241 related articles for article (PubMed ID: 38286636)
21. Cannabidiol in the treatment of epilepsy: Current evidence and perspectives for further research.
Franco V; Bialer M; Perucca E
Neuropharmacology; 2021 Mar; 185():108442. PubMed ID: 33347884
[TBL] [Abstract][Full Text] [Related]
22. Pharmacological and Therapeutic Properties of Cannabidiol for Epilepsy.
Franco V; Perucca E
Drugs; 2019 Sep; 79(13):1435-1454. PubMed ID: 31372958
[TBL] [Abstract][Full Text] [Related]
23. A phase 1, randomized, pharmacokinetic trial of the effect of different meal compositions, whole milk, and alcohol on cannabidiol exposure and safety in healthy subjects.
Crockett J; Critchley D; Tayo B; Berwaerts J; Morrison G
Epilepsia; 2020 Feb; 61(2):267-277. PubMed ID: 32012251
[TBL] [Abstract][Full Text] [Related]
24. Cannabidiol Adverse Effects and Toxicity.
Huestis MA; Solimini R; Pichini S; Pacifici R; Carlier J; Busardò FP
Curr Neuropharmacol; 2019; 17(10):974-989. PubMed ID: 31161980
[TBL] [Abstract][Full Text] [Related]
25. A Phase 2, Double-Blind, Placebo-Controlled Trial to Investigate Potential Drug-Drug Interactions Between Cannabidiol and Clobazam.
VanLandingham KE; Crockett J; Taylor L; Morrison G
J Clin Pharmacol; 2020 Oct; 60(10):1304-1313. PubMed ID: 32652616
[TBL] [Abstract][Full Text] [Related]
26. Clinical efficacy and safety of cannabidiol for pediatric refractory epilepsy indications: A systematic review and meta-analysis.
Talwar A; Estes E; Aparasu R; Reddy DS
Exp Neurol; 2023 Jan; 359():114238. PubMed ID: 36206805
[TBL] [Abstract][Full Text] [Related]
27. Cannabidiol efficacy independent of clobazam: Meta-analysis of four randomized controlled trials.
Devinsky O; Thiele EA; Wright S; Checketts D; Morrison G; Dunayevich E; Knappertz V
Acta Neurol Scand; 2020 Dec; 142(6):531-540. PubMed ID: 32592183
[TBL] [Abstract][Full Text] [Related]
28. Cannabidiol: A Review of Clinical Efficacy and Safety in Epilepsy.
Samanta D
Pediatr Neurol; 2019 Jul; 96():24-29. PubMed ID: 31053391
[TBL] [Abstract][Full Text] [Related]
29. The cannabidiol conundrum: potential benefits and risks of cannabidiol products for children.
Singer L; Tokish H; Park F; Campisi C; Milanaik RL
Curr Opin Pediatr; 2020 Feb; 32(1):198-205. PubMed ID: 31833952
[TBL] [Abstract][Full Text] [Related]
30. A Phase II Randomized Trial to Explore the Potential for Pharmacokinetic Drug-Drug Interactions with Stiripentol or Valproate when Combined with Cannabidiol in Patients with Epilepsy.
Ben-Menachem E; Gunning B; Arenas Cabrera CM; VanLandingham K; Crockett J; Critchley D; Wray L; Tayo B; Morrison G; Toledo M
CNS Drugs; 2020 Jun; 34(6):661-672. PubMed ID: 32350749
[TBL] [Abstract][Full Text] [Related]
31. Cannabidiol for the treatment of Lennox-Gastaut syndrome and Dravet syndrome: experts' recommendations for its use in clinical practice in Spain.
García-Peñas JJ; Gil Nagel-Rein A; Sánchez-Carpintero R; Villanueva-Haba V
Rev Neurol; 2021 Sep; 73(S01):S1-S8. PubMed ID: 34486101
[TBL] [Abstract][Full Text] [Related]
32. The efficacy and safety of cannabidiol (CBD) in pediatric patients with Dravet Syndrome: a narrative review of clinical trials.
Aderinto N; Olatunji G; Kokori E; Ajayi YI; Akinmoju O; Ayedun AS; Ayoola OI; Aderinto NO
Eur J Med Res; 2024 Mar; 29(1):182. PubMed ID: 38500226
[TBL] [Abstract][Full Text] [Related]
33. Cannabidiol Therapy for Refractory Epilepsy and Seizure Disorders.
Golub V; Reddy DS
Adv Exp Med Biol; 2021; 1264():93-110. PubMed ID: 33332006
[TBL] [Abstract][Full Text] [Related]
34. A Phase 1, Randomised, Placebo-Controlled, Dose Escalation Study to Investigate the Safety, Tolerability and Pharmacokinetics of Cannabidiol in Fed Healthy Volunteers.
Perkins D; Butler J; Ong K; Nguyen TH; Cox S; Francis B; Mcintosh M; Lilley B
Eur J Drug Metab Pharmacokinet; 2020 Oct; 45(5):575-586. PubMed ID: 32409982
[TBL] [Abstract][Full Text] [Related]
35. Hepatotoxicity of a Cannabidiol-Rich Cannabis Extract in the Mouse Model.
Ewing LE; Skinner CM; Quick CM; Kennon-McGill S; McGill MR; Walker LA; ElSohly MA; Gurley BJ; Koturbash I
Molecules; 2019 Apr; 24(9):. PubMed ID: 31052254
[TBL] [Abstract][Full Text] [Related]
36. Efficacy and Safety of Cannabidiol in Epilepsy: A Systematic Review and Meta-Analysis.
Lattanzi S; Brigo F; Trinka E; Zaccara G; Cagnetti C; Del Giovane C; Silvestrini M
Drugs; 2018 Nov; 78(17):1791-1804. PubMed ID: 30390221
[TBL] [Abstract][Full Text] [Related]
37. Pharmacokinetics of cannabidiol in children with refractory epileptic encephalopathy.
Cáceres Guido P; Riva N; Caraballo R; Reyes G; Huaman M; Gutierrez R; Agostini S; Fabiana Delaven S; Pérez Montilla CA; García Bournissen F; Schaiquevich P
Epilepsia; 2021 Jan; 62(1):e7-e12. PubMed ID: 33280111
[TBL] [Abstract][Full Text] [Related]
38. Does cannabidiol have antiseizure activity independent of its interactions with clobazam? An appraisal of the evidence from randomized controlled trials.
Bialer M; Perucca E
Epilepsia; 2020 Jun; 61(6):1082-1089. PubMed ID: 32452568
[TBL] [Abstract][Full Text] [Related]
39. Use of cannabidiol in the treatment of epilepsy.
Mazurkiewicz-Bełdzińska M; Zawadzka M
Neurol Neurochir Pol; 2022; 56(1):14-20. PubMed ID: 35211946
[TBL] [Abstract][Full Text] [Related]
40. Current application of cannabidiol (CBD) in the management and treatment of neurological disorders.
Fiani B; Sarhadi KJ; Soula M; Zafar A; Quadri SA
Neurol Sci; 2020 Nov; 41(11):3085-3098. PubMed ID: 32556748
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
